Mindset Pharma Inc. (Mindset), a drug discovery and development company focused on creating optimized and patentable next-generation microdose psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, filed an international patent application covering its Family 3 novel psychedelic compounds. Mindset’s Family 3 consists of certain compounds that have demonstrated half-lives extending well beyond those exhibited by comparable classical psychedelic drugs with no significant reduction in binding affinity at the serotonin 5-HT2A receptor.
Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, and an innovative process to chemically synthesize psilocybin, as well as its own proprietary compounds.
This was reported by Mindset Pharma Inc. on December 28, 2021.
Contact information: McKenna Miller, KCSA Strategic Communications for Mindset Pharma Inc., 217 Queen Street West, Suite 401, Toronto, Ontario M5V 0R2, Canada; 949-606-6585; Email: MindSet@kcsa.com; Website: https://www.mindsetpharma.com/
